| Abstract |
One of the newly discovered tumor suppressor genes is fragile histidine triad (FHIT) gene located on chromosome 3P14.2. Its abnormal transcripts are detected in several human cancers. Deletions of the short arm of chromosome 3,on which at least 3 genes are positioned, are observed in various tumors as head and neck, breast, GIT, oesophageal and cervical cancers.
Immunohistochemical staining for FHIT protein done in many organs showing loss of FHIT expression in high percentage of primary oesophageal carcinoma, non-small cell lung carcinoma, breast cancer, gastric carcinoma, pancreatic carcinoma and colorectal carcinoma.
Inactivation of FHIT gene is an important genetic event associated with genesis of endometrial carcinoma, especially with tumors of higher histopathologic grade which are believed to emerge directly from atrophic endometrium.
This study aimed at evaluation of immunohistochemical localization of FHIT gene in malignant and premalignant lesions of the endometrium in relation to tumor behavior.
Materials and Methods:
A retrospective study was performed on selected cases of different endometrial lesions (simple, complex, atypical hyperplasia and adenocarcinoma GI, II, III). 4-5 microns thick sections was cut from each formaline-fixed, paraffin-embedded tissues and submitted to immunohistochemical staining for detection of FHIT protein. The immunohistochemical findings was evaluated in relation to histopathological data
Summary and conclusion
Fifty-two cases of endometrial lesions, benign and malignant, were studied histopathologically (for typing of the lesion, grading of the tumors, detection of mean apoptotic index in different lesions, and other histopathological changes in different grades) and immunohistochemically |
